The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes. Issue 3 (March 2022)

• Record Type: Journal Article
• Authors: Klotz, Rosa; Hackert, Thilo; Heger, Patrick; Probst, Pascal; Hinz, Ulf; Loos, Martin; Berchtold, Christoph; Mehrabi, Arianeb; Schneider, Martin; Müller-Stich, Beat P.; Strobel, Oliver; Diener, Markus K.; Mihaljevic, André L.; Büchler, Markus W.
• Is Part Of: HPB. Volume 24:Issue 3(2022)
• Page Start: 332
• Page End: 341
• Publication Date: 2022-03
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1016/j.hpb.2021.06.432
• Languages: English
• ISSNs: 1365-182X

Abstract

Abstract: Background: Surgical resection is the mainstay of potential cure for patients with pancreatic cancer, however, local recurrence is frequent. Previously, we have described an extended resection technique for pancreatoduodenectomy aiming at a radical resection of the nerve and lymphatic tissue between celiac artery, superior mesenteric artery and mesenteric–portal axis (TRIANGLE operation). Until now, data on postoperative outcome have not been reported, yet. Methods: Patients who underwent either partial (PD) or total pancreatoduodenectomy (TP) applying the TRIANGLE procedure were identified. These cohorts were compared to matched historic cohorts with standard resections. Results: Overall, 330 patients were analysed (PDTRIANGLE and PDSTANDARD, each n = 108; TPTRIANGLE and TPSTANDARD, each n = 57). More lymph nodes were harvested in TRIANGLE compared to standard resection (PD: 27.5 (21–35) versus 31.5 (24–40); P = 0.0187, TP: 33 (28–49) versus 44 (29–53); P = 0.3174) and the rate of tumour positive resections margins, R1(direct), dropped. Duration of operation was significantly longer and blood loss higher. Postoperative mortality and complications did not differ significantly. Conclusion: Pancreatoduodenectomy according to the TRIANGLE protocol can be performed without increased morbidity and mortality at a high-volume centre. Long-term survival and quality of life need to be investigated in prospective clinical trials with adequate sample size.